Drug-induced blood pressure increase – recommendations for assessment in clinical and non-clinical studies

References

• Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014 Jan 21;129(3):399–410.
   PubMed Web of Science ®Google Scholar
• Gillespie CD, Hurvitz KA. Prevalence of hypertension and controlled hypertension - United States, 2007-2010. MMWR Suppl. 2013 Nov 22;62(3):144–148.
   PubMedGoogle Scholar
• D’Agostino RB Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008 Feb 12;117(6):743–753.
   PubMed Web of Science ®Google Scholar
• MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990 Mar 31;335(8692):765–774.
   PubMed Web of Science ®Google Scholar
• Sacco RL, Benjamin EJ, Broderick JP, et al. American Heart Association prevention conference. IV. Prevention and rehabilitation of stroke. Risk factors. Stroke. 1997 Jul;28(7):1507–1517.
   PubMed Web of Science ®Google Scholar
• Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001 Nov 1;345(18):1291–1297.
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903–1913.
   PubMed Web of Science ®Google Scholar
• Sundstrom J, Arima H, Jackson R, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med. 2015 Feb 3;162(3):184–191.
   PubMed Web of Science ®Google Scholar
• Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile. A statement for health professionals. Circulation. 1991 Jan;83(1):356–362.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003 Dec;42(6):1206–1252.
   PubMed Web of Science ®Google Scholar
• Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA. 2002 Oct 16;288(15):1882–1888.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31(7):1281–1357.
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507–520.
   PubMed Web of Science ®Google Scholar
• Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014 Jan;32(1):3–15.
   PubMed Web of Science ®Google Scholar
• Wright JT Jr., Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015 Nov 26;373(22):2103–2116.
   PubMed Web of Science ®Google Scholar
• Elliott WJ. Drug interactions and drugs that affect blood pressure. J Clin Hypertens (Greenwich). 2006 Oct;8(10):731–737.
   PubMedGoogle Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005 Mar 17;352(11):1092–1102.
   PubMed Web of Science ®Google Scholar
• Mouhayar E, Salahudeen A. Hypertension in cancer patients. Tex Heart Inst J. 2011;38(3):263–265.
   PubMed Web of Science ®Google Scholar
• Grossman A, Messerli FH, Grossman E. Drug induced hypertension–an unappreciated cause of secondary hypertension. Eur J Pharmacol. 2015 Sep 15;763(Pt A):15–22.
   PubMed Web of Science ®Google Scholar
• Boldo A, White WB. Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies. Endocrinol Metab Clin North Am. 2011 Jun;40(2):419–432. ix.
   PubMed Web of Science ®Google Scholar
• Boyle SM, Berns JS. Erythropoietin and resistant hypertension in CKD. Semin Nephrol. 2014;34(5):540–549.
   PubMed Web of Science ®Google Scholar
• Hoorn EJ, Walsh SB, McCormick JA, et al. Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol. 2012 May–Jun;25(3):269–275.
   PubMed Web of Science ®Google Scholar
• Johnson AG, Nguyen TV, Owe-Young R, et al. Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1. J Hum Hypertens. 1996 Apr;10(4):257–261.
   PubMed Web of Science ®Google Scholar
• International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Safety pharmacology studies for human pharmaceuticals S7A. 2000 [cited 2016 May 24]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf
   Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007 Nov 22;357(21):2109–2122.
   PubMed Web of Science ®Google Scholar
• Sager P, Heilbraun J, Turner JR, et al. Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. Am Heart J. 2013 Apr;165(4):477–488.
   PubMed Web of Science ®Google Scholar
• Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010 May 5;102(9):596–604.
   PubMedGoogle Scholar
• Kruzliak P, Novak J, Novak M. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors. Am J Hypertens. 2014 Jan;27(1):3–13.
   PubMed Web of Science ®Google Scholar
• Textor SC, Taler SJ, Canzanello VJ, et al. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl. 2000 Sep;6(5):521–530.
   PubMed Web of Science ®Google Scholar
• Snowden S, Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol Rev. 2011 Jul–Aug;19(4):184–191.
   PubMed Web of Science ®Google Scholar
• Sowers JR, White WB, Pitt B, et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005 Jan 24;165(2):161–168.
   PubMed Web of Science ®Google Scholar
• White WB. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension. 2007 Mar;49(3):408–418.
   PubMed Web of Science ®Google Scholar
• Pickering TG, White WB. ASH position paper: home and ambulatory blood pressure monitoring. When and how to use self (home) and ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2008 Nov;10(11):850–855.
   PubMed Web of Science ®Google Scholar
• James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010 Sep 2;363(10):905–917.
   PubMed Web of Science ®Google Scholar
• Jordan J, Scholze J, Matiba B, et al. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes. 2005 May;29(5):509–516.
   Web of Science ®Google Scholar
• Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010 Mar 13;375(9718):895–905.
   PubMed Web of Science ®Google Scholar
• Kim ES, Samuels TA, Yeh HC, et al. End-digit preference and the quality of blood pressure monitoring in diabetic adults. Diabetes Care. 2007 Aug;30(8):1959–1963.
   PubMed Web of Science ®Google Scholar
• Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005 Jul;46(1):156–161.
   PubMed Web of Science ®Google Scholar
• O’Brien E, Parati G, Stergiou G. Ambulatory blood pressure measurement: what is the international consensus? Hypertension. 2013 Dec;62(6):988–994.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension. 1994 Dec;24(6):793–801.
   PubMed Web of Science ®Google Scholar
• Clement DL, De Buyzere M. Office versus Ambulatory (OvA) recording of blood pressure, a European multicenter study: inclusion and early follow-up characteristics. Blood Press Monit. 1998 Jun;3(3):167–172.
   PubMedGoogle Scholar
• Hansen TW, Kikuya M, Thijs L, et al. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals. J Hypertens. 2007 Aug;25(8):1554–1564.
   PubMed Web of Science ®Google Scholar
• Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006 May;47(5):846–853.
   PubMed Web of Science ®Google Scholar
• Stergiou GS, Baibas NM, Kalogeropoulos PG. Cardiovascular risk prediction based on home blood pressure measurement: the Didima study. J Hypertens. 2007 Aug;25(8):1590–1596.
   PubMed Web of Science ®Google Scholar
• Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005 Jan;45(1):142–161.
   PubMed Web of Science ®Google Scholar
• O’Brien E, Atkins N, Stergiou G, et al. European Society of Hypertension International Protocol revision 2010 for the validation of blood pressure measuring devices in adults. Blood Press Monit. 2010 Feb;15(1):23–38.
   PubMed Web of Science ®Google Scholar
• Mancia G, Omboni S, Parati G, et al. Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. J Hypertens. 2001 Oct;19(10):1755–1763.
   PubMed Web of Science ®Google Scholar
• MacDonald TM, Richard D, Lheritier K, et al. The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents. Int J Clin Pract. 2010 May;64(6):746–755.
   PubMed Web of Science ®Google Scholar
• Townsend R, Bittar N, Rosen J, et al. Blood pressure effects of naproxcinod in hypertensive patients. J Clin Hypertens (Greenwich). 2011 May;13(5):376–384.
   PubMed Web of Science ®Google Scholar
• Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007 Oct 6;370(9594):1219–1229.
   PubMed Web of Science ®Google Scholar
• White WB, Giles T, Bakris GL, et al. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J. 2006 Jan;151(1):176–184.
   PubMed Web of Science ®Google Scholar
• Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on ambulatory monitoring of blood pressure and Lisinopril evaluation. Circulation. 1997 Mar 18;95(6):1464–1470.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Cavallini C. Ambulatory blood pressure for cardiovascular risk stratification. Circulation. 2007 Apr 24;115(16):2091–2093.
   PubMed Web of Science ®Google Scholar
• Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the second international consensus conference on home blood pressure monitoring. J Hypertens. 2008 Aug;26(8):1505–1526.
   PubMed Web of Science ®Google Scholar
• Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens. 2010 Dec;24(12):779–785.
   PubMed Web of Science ®Google Scholar
• Campbell P, White WB. Home monitoring of the blood pressure. In: Black HR, Elliot WJ, editors. Hypertension: companion to Braunwald’s cardiovascular medicine. WB Saunders; 2012.
   Google Scholar
• Ward AM, Takahashi O, Stevens R, et al. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens. 2012 Mar;30(3):449–456.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). 2010 [cited 2016 May 24]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
   Google Scholar
• Bowes J, Brown AJ, Hamon J, et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov. 2012 Dec;11(12):909–922.
   PubMed Web of Science ®Google Scholar
• Authier S, Pugsley MK, Curtis MJ. Haemodynamic assessment in safety pharmacology. Handb Exp Pharmacol. 2015;229:221–241.
   PubMedGoogle Scholar
• Skinner M, Philp K, Lengel D, et al. The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation. Br J Pharmacol. 2014 May;171(9):2308–2320.
   PubMed Web of Science ®Google Scholar
• Dixit R, Iciek LA, McKeever K, et al. Challenges of general safety evaluations of biologics compared to small molecule pharmaceuticals in animal models. Expert Opin Drug Discov. 2010 Jan;5(1):79–94.
   PubMed Web of Science ®Google Scholar
• Vargas HM, Amouzadeh HR, Engwall MJ. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals. Expert Opin Drug Saf. 2013 Jan;12(1):91–102.
   PubMed Web of Science ®Google Scholar
• De Haan L. Preclinical safety considerations for teh development of antibody-based therapeutics. In: Tabrizi MA, Bornstein GG, Klakamp SL, editors. Development of antibody-based therapeutics. New York (NY): Springer Science; 2012.
   Google Scholar
• Vargas HM, Bass AS, Breidenbach A, et al. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods. 2008 Sep–Oct;58(2):72–76.
   PubMedGoogle Scholar
• International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Preclinical safety evaluation of biotechnology-derived pharmaceuticals S6(R1). 2011 [cited 2016 May 24]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf
   Google Scholar
• De Haan L, Henderson S, McFarlane M, et al. Species selection. Eur Biopharm Rev. 2011;2011:40–44.
   Google Scholar
• Leung AA, Nerenberg K, Daskalopoulou SS, et al. Hypertension Canada’s 2016 Canadian Hypertension Education Program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2016 May;32(5):569–588.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. 2011 [cited 2016 18 Aug]; Available from: https://www.nice.org.uk/guidance/cg127/resources/hypertension-in-adults-diagnosis-and-management-35109454941637
   Google Scholar
• U.S. Preventive Services Task Force. Hypertension in adults: screening and home monitoring. 2015 [cited 2016 Aug 18]. Available from: http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/high-blood-pressure-in-adults-screening
   Google Scholar
• Ewart L, Aylott M, Deurinck M, et al. The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative. Toxicol Sci. 2014 Dec;142(2):427–435.
   PubMed Web of Science ®Google Scholar
• Steidl-Nichols J Cross species translation of drug-induced heart rate and blood pressure effects, how predictive are our preclinical models? 2015 [cited 2016 May 12]. Available from: http://www.safetypharmacology.org/Webinars/Nonclinical/Authier_Intro.pdf
   Google Scholar
• Netea RT, Lenders JW, Smits P, et al. Both body and arm position significantly influence blood pressure measurement. J Hum Hypertens. 2003 Jul;17(7):459–462.
   PubMed Web of Science ®Google Scholar
• Terra SG, Blum RA, Wei GC, et al. Evaluation of methods for improving precision of blood pressure measurements in phase I clinical trials. J Clin Pharmacol. 2004 May;44(5):457–463.
   PubMed Web of Science ®Google Scholar
• Ogedegbe G, Pickering T. Principles and techniques of blood pressure measurement. Cardiol Clin. 2010 Nov;28(4):571–586.
   PubMed Web of Science ®Google Scholar
• Seltzer JH, Turner JR, Geiger MJ, et al. Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research Consortium. Am Heart J. 2015 Feb;169(2):197–204.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014 Feb;23(1):3–16.
   PubMed Web of Science ®Google Scholar